GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
MXPA02006338A
(en)
|
1999-12-24 |
2002-12-13 |
Aventis Pharma Ltd |
Azaindoles.
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
AU2001277621A1
(en)
*
|
2000-08-09 |
2002-03-04 |
Astrazeneca Ab |
Antiangiogenic bicyclic derivatives
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
ZA200301703B
(en)
*
|
2000-09-15 |
2004-03-02 |
Vertex Pharma |
Pyrazole compounds useful as protein kinase inhibitors.
|
EP1698627A1
(en)
*
|
2000-09-15 |
2006-09-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
EP1317449B1
(en)
*
|
2000-09-15 |
2006-05-31 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
ATE430742T1
(en)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
PYRIMIDINAMINES AS ANGIOGENESIS MODULATORS
|
AU2006201228B2
(en)
*
|
2000-12-21 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole Compounds Useful as Protein Kinase Inhibitors
|
ES2265450T3
(en)
*
|
2000-12-21 |
2007-02-16 |
Vertex Pharmaceuticals Incorporated |
PIRAZOL COMPOUNDS USED AS INHIBITORS OF PROTEIN QUINASA.
|
US6756374B2
(en)
|
2001-01-22 |
2004-06-29 |
Hoffmann-La Roche Inc. |
Diaminothiazoles having antiproliferative activity
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0115109D0
(en)
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
DE60227709D1
(en)
*
|
2001-06-29 |
2008-08-28 |
Ab Science |
THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
JP2004537537A
(en)
*
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
Uses of tyrosine kinase inhibitors to treat inflammatory diseases
|
US20040266797A1
(en)
*
|
2001-06-29 |
2004-12-30 |
Alain Moussy |
Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
|
WO2003002106A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
US7727731B2
(en)
*
|
2001-06-29 |
2010-06-01 |
Ab Science |
Potent, selective and non toxic c-kit inhibitors
|
ATE343415T1
(en)
*
|
2001-06-29 |
2006-11-15 |
Ab Science |
THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
|
JO3429B1
(en)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
Hiv inhibiting pyrimidines derivatives
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
US6939874B2
(en)
*
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
JP2005507917A
(en)
*
|
2001-09-20 |
2005-03-24 |
アブ サイエンス |
Methods of using tyrosine kinase inhibitors to promote hair growth
|
EP1427379B1
(en)
*
|
2001-09-20 |
2008-08-13 |
AB Science |
Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
|
WO2003026664A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Corporation |
2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
RU2004116068A
(en)
*
|
2001-10-25 |
2005-03-20 |
Висконсин Элумни Рисерч Фаундейшн (Us) |
VASCULAR STENT OR TRANSPLANT, COATING OR IMPREGNATED PROTEIN INHIBITORS
|
AU2002363176B2
(en)
*
|
2001-11-01 |
2008-09-25 |
Janssen Pharmaceutica N.V. |
Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors)
|
SE0104140D0
(en)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
GB0129476D0
(en)
*
|
2001-12-10 |
2002-01-30 |
Syngenta Participations Ag |
Organic compounds
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
AU2003215087B2
(en)
*
|
2002-02-06 |
2009-07-16 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds useful as inhibitors of GSK-3
|
CA2476281A1
(en)
|
2002-02-08 |
2003-08-14 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
EP1478380B1
(en)
*
|
2002-02-27 |
2006-08-02 |
AB Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
AU2003208479A1
(en)
|
2002-03-09 |
2003-09-22 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
DE60332604D1
(en)
*
|
2002-03-15 |
2010-07-01 |
Vertex Pharma |
AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
|
DE60332433D1
(en)
*
|
2002-03-15 |
2010-06-17 |
Vertex Pharma |
AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR
|
WO2003078426A1
(en)
|
2002-03-15 |
2003-09-25 |
Vertex Pharmaceuticals, Inc. |
Azolylaminoazine as inhibitors of protein kinases
|
CA2489648A1
(en)
*
|
2002-06-17 |
2003-12-24 |
Smithkline Beecham Corporation |
Chemical process
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
EP2316459B1
(en)
*
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
|
DK1534286T3
(en)
|
2002-07-29 |
2010-04-26 |
Rigel Pharmaceuticals Inc |
Methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
ES2273043T3
(en)
|
2002-08-02 |
2007-05-01 |
Vertex Pharmaceuticals Incorporated |
PIRAZOL COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3.
|
MXPA05001541A
(en)
|
2002-08-09 |
2005-04-19 |
Janssen Pharmaceutica Nv |
Processes for the preparation of 4-[[4-[[4 -(2-cyanoethenyl)-2, 6-dimethylphenyl] amino]-2 -pyrimidinyl] amino] benzonitrile.
|
ES2273047T3
(en)
*
|
2002-10-28 |
2007-05-01 |
Bayer Healthcare Ag |
PHENYLAMINOPIRIMIDINES REPLACED WITH HETEROARILOXI AS INHIBITORS OF RHO-CINASA.
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
PL379330A1
(en)
|
2002-12-20 |
2006-08-21 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
US20040121968A1
(en)
*
|
2002-12-23 |
2004-06-24 |
Alexander Ljubimov |
Antiangiogenesis by inhibiting protein kinase CK2 activity
|
US7601718B2
(en)
*
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
US7514446B2
(en)
|
2003-02-20 |
2009-04-07 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
EP1644365A2
(en)
*
|
2003-07-02 |
2006-04-12 |
Biofocus Discovery Ltd |
Pyrazine and pyridine derivatives as rho kinase inhibitors
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
PT1656372E
(en)
|
2003-07-30 |
2013-06-27 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
CA2533870A1
(en)
*
|
2003-07-30 |
2005-02-10 |
Shudong Wang |
Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
|
NZ585188A
(en)
|
2003-08-15 |
2011-09-30 |
Novartis Ag |
2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
GB0321710D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
WO2005033086A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
DE602004022187D1
(en)
|
2003-10-17 |
2009-09-03 |
Astrazeneca Ab |
4- (PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
|
US20050107374A1
(en)
*
|
2003-10-21 |
2005-05-19 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
MY141220A
(en)
*
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
WO2005056547A2
(en)
*
|
2003-12-04 |
2005-06-23 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
AU2005205118B2
(en)
*
|
2004-01-09 |
2009-02-26 |
Novartis Ag |
Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors
|
AU2005205167A1
(en)
*
|
2004-01-16 |
2005-07-28 |
Novartis Ag |
2, 4 - diaminopyrimidines and their use for inducing cardiomyogenesis
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
CA2560269A1
(en)
*
|
2004-03-19 |
2005-09-29 |
The Penn State Research Foundation |
Combinatorial methods and compositions for treatment of melanoma
|
MXPA06011327A
(en)
*
|
2004-03-30 |
2006-12-15 |
Vertex Pharma |
Azaindoles useful as inhibitors of jak and other protein kinases.
|
US7211576B2
(en)
|
2004-04-20 |
2007-05-01 |
Hoffmann-La Roche Inc. |
Diaminothiazoles
|
JP2007537235A
(en)
|
2004-05-14 |
2007-12-20 |
ファイザー・プロダクツ・インク |
Pyrimidine derivatives for the treatment of abnormal cell proliferation
|
EP1758887A1
(en)
|
2004-05-14 |
2007-03-07 |
Pfizer Products Incorporated |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
CA2566332A1
(en)
|
2004-05-14 |
2005-11-24 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
CA2566531A1
(en)
|
2004-05-18 |
2005-12-15 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
PE20060664A1
(en)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
BICYCLE AMIDAS AS KINASE INHIBITORS
|
CA2580838A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
US7776869B2
(en)
*
|
2004-10-18 |
2010-08-17 |
Amgen Inc. |
Heteroaryl-substituted alkyne compounds and method of use
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
RU2007122485A
(en)
|
2004-11-17 |
2008-12-27 |
Мийкана Терапьютикс |
KINASE INHIBITORS
|
US7557207B2
(en)
|
2004-11-24 |
2009-07-07 |
Rigel Pharmaceuticals, Inc. |
Spiro 2,4-pyrimidinediamine compounds and their uses
|
CA2590110C
(en)
|
2004-12-30 |
2014-06-03 |
Exelixis, Inc. |
Kinase modulators and method of use
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
EP1846394B1
(en)
|
2005-02-04 |
2011-10-26 |
AstraZeneca AB |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
DE602006001515D1
(en)
|
2005-02-16 |
2008-07-31 |
Astrazeneca Ab |
CHEMICAL COMPOUNDS
|
WO2006091737A1
(en)
*
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
TW200716551A
(en)
|
2005-03-10 |
2007-05-01 |
Cgi Pharmaceuticals Inc |
Certain substituted amides, method of making, and method of use thereof
|
US20080287437A1
(en)
|
2005-05-16 |
2008-11-20 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
|
WO2006129100A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Glaxo Group Limited |
Novel compounds
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
NZ563454A
(en)
|
2005-06-08 |
2011-03-31 |
Rigel Pharmaceuticals Inc |
2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
|
PL1899329T3
(en)
*
|
2005-07-01 |
2012-03-30 |
Irm Llc |
Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
|
AR054834A1
(en)
*
|
2005-07-15 |
2007-07-18 |
Glaxo Group Ltd |
DERIVATIVES OF 1,1-DIOXIDE-2,3-DIHIDRO-1,2-BENZOISOTIAZOL-6-IL-1H-INDAZOL-4-IL-2,4 PYRIMIDINE DIAMINE
|
WO2007028445A1
(en)
*
|
2005-07-15 |
2007-03-15 |
Glaxo Group Limited |
6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
|
ATE484501T1
(en)
|
2005-07-26 |
2010-10-15 |
Vertex Pharma |
BENZIMIDAZOLES USABLE AS PROTEIN KINASE INHIBITORS
|
EP1917259B1
(en)
*
|
2005-08-18 |
2012-01-25 |
Vertex Pharmaceuticals Incorporated |
Pyrazine kinase inhibitors
|
PE20070425A1
(en)
|
2005-08-24 |
2007-07-02 |
Wyeth Corp |
PHARMACEUTICAL COMPOSITION INCLUDING 1- [4- (2-AZEPAN-1-IL-ETOXY) -BENZYL] -2- (4-HYDROXYPHENYL) -3-METHYL-1H-INDOL-5-OL ACETATE (BAZEDOXIFENO ACETATE) AS A SELECTIVE MODULATOR OF THE ESTROGEN RECEPTOR
|
KR20080049130A
(en)
|
2005-09-30 |
2008-06-03 |
아스트라제네카 아베 |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
EP1928456B1
(en)
|
2005-09-30 |
2015-04-22 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
GB0520958D0
(en)
|
2005-10-14 |
2005-11-23 |
Cyclacel Ltd |
Compound
|
US20080287475A1
(en)
|
2005-10-28 |
2008-11-20 |
Astrazeneca Ab |
4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
|
MY167260A
(en)
*
|
2005-11-01 |
2018-08-14 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
BRPI0619704A2
(en)
*
|
2005-11-03 |
2011-10-11 |
Vertex Pharma |
compound, composition, method for inhibiting aurora kinase activity in a biological sample, method for treating a proliferative disorder and method for treating cancer
|
US7705009B2
(en)
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
EP2559694A3
(en)
|
2006-01-17 |
2013-04-03 |
Vertex Pharmaceuticals, Inc. |
Azaindoles useful as inhibitors of Janus kinases
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2007085540A1
(en)
*
|
2006-01-27 |
2007-08-02 |
Glaxo Group Limited |
1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
|
AU2007227602A1
(en)
*
|
2006-03-16 |
2007-09-27 |
Novartis Ag |
Heterocyclic organic compounds for the treatment of in particular melanoma
|
CN101506175A
(en)
*
|
2006-06-15 |
2009-08-12 |
贝林格尔·英格海姆国际有限公司 |
2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
|
WO2008005538A2
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
AU2007293917B2
(en)
|
2006-09-08 |
2013-01-31 |
F. Hoffmann-La Roche Ag |
Benzotriazole kinase modulators
|
US20090054507A1
(en)
*
|
2006-09-12 |
2009-02-26 |
Cleveland State University |
Control of malignant cells by kinase inhibition
|
US20100048657A1
(en)
*
|
2006-09-12 |
2010-02-25 |
Cleveland State University |
Control of malignant cells proliferation through the inhibition of casein kinase 2
|
JP2010509231A
(en)
*
|
2006-11-02 |
2010-03-25 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
WO2008063933A2
(en)
|
2006-11-10 |
2008-05-29 |
Massachusetts Institute Of Technology |
Pak modulators
|
KR101149295B1
(en)
*
|
2006-12-08 |
2012-07-05 |
아이알엠 엘엘씨 |
Compounds as protein kinase inhibitors
|
KR101152162B1
(en)
|
2006-12-08 |
2012-07-10 |
에프. 호프만-라 로슈 아게 |
Substituted pyrimidines and their use as jnk modulators
|
CN101616895A
(en)
|
2006-12-08 |
2009-12-30 |
Irm责任有限公司 |
Compound and composition as kinases inhibitor
|
CA2673353A1
(en)
*
|
2006-12-19 |
2008-06-26 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
CA2679884A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
EP2134709A1
(en)
|
2007-03-09 |
2009-12-23 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines useful as inhibitors of protein kinases
|
WO2008112651A2
(en)
*
|
2007-03-09 |
2008-09-18 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
EP2137186B1
(en)
*
|
2007-03-23 |
2016-01-27 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
NZ580343A
(en)
|
2007-04-13 |
2012-03-30 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
CA2684470C
(en)
|
2007-04-16 |
2016-02-09 |
Hutchison Medipharma Enterprises Limited |
Pyrimidine derivatives
|
WO2008137621A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
MX2009011810A
(en)
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Thiazoles and pyrazoles useful as kinase inhibitors.
|
MX2009011811A
(en)
*
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors.
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
JP2010528021A
(en)
*
|
2007-05-24 |
2010-08-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Thiazoles and pyrazoles useful as kinase inhibitors
|
WO2008154026A1
(en)
*
|
2007-06-11 |
2008-12-18 |
Miikana Therapeutics, Inc. |
Substituted pyrazole compounds
|
BRPI0814821A2
(en)
*
|
2007-07-16 |
2015-02-03 |
Astrazeneca Ab |
COMPOUND, PHARMACEUTICAL COMPOSITION, AND, PROCESS TO PREPARE A COMPOUND
|
TW200916468A
(en)
|
2007-07-31 |
2009-04-16 |
Vertex Pharma |
Process for preparing 5-fluoro-1H-pyrazolo[3,4-b]pyridin-3-amine and derivatives thereof
|
US8440681B2
(en)
|
2007-08-28 |
2013-05-14 |
Irm Llc |
2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
|
WO2009065132A1
(en)
*
|
2007-11-16 |
2009-05-22 |
Oklahoma Medical Research Foundation |
Predicting and diagnosing patients with autoimmune disease
|
JP2011032169A
(en)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
4-aminopyrimidine derivative and medicinal composition containing the compound
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
SI2300013T1
(en)
*
|
2008-05-21 |
2018-03-30 |
Adriad Pharmacaceuticals, Inc. |
Phosphorous derivatives as kinase inhibitors
|
AU2013205506B2
(en)
*
|
2008-05-21 |
2016-04-21 |
Takeda Pharmaceutical Company Limited |
Phosphorous derivatives as kinase inhibitors
|
MX2011000026A
(en)
|
2008-06-23 |
2011-02-24 |
Vertex Pharma |
Protein kinase inhibitors.
|
PE20100087A1
(en)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
|
DK2361248T3
(en)
|
2008-06-27 |
2019-01-14 |
Celgene Car Llc |
Heteroberl compounds and uses thereof
|
US8338439B2
(en)
*
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US20100016247A1
(en)
*
|
2008-07-21 |
2010-01-21 |
Florida State University Research Foundation |
Using budding yeast to screen for inhibitors of aurora kinases
|
MX2011002312A
(en)
*
|
2008-09-03 |
2011-04-26 |
Vertex Pharma |
Co-crystals and pharmaceutical formulations comprising the same.
|
AU2009290617B2
(en)
*
|
2008-09-15 |
2015-05-14 |
Fundacion Ciencia Para La Vida |
Methods and compositions for modulating Ire1, Src, and Abl activity
|
US20110178142A1
(en)
*
|
2008-10-13 |
2011-07-21 |
National Institute Of Immunology |
Pharmaceutical composition for therapeutic or prophylactic treatment of bacterial infections and associated diseases
|
WO2010049731A1
(en)
*
|
2008-10-29 |
2010-05-06 |
Astrazeneca Ab |
Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors
|
JO2885B1
(en)
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
ES2659725T3
(en)
|
2009-05-05 |
2018-03-19 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and disorder treatment procedure
|
US8536180B2
(en)
*
|
2009-05-27 |
2013-09-17 |
Abbvie Inc. |
Pyrimidine inhibitors of kinase activity
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
GEP20156325B
(en)
|
2009-06-17 |
2015-07-10 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
KR101246911B1
(en)
|
2009-11-02 |
2013-03-25 |
한국화학연구원 |
Novel 2,4-pyrimidine derivatives and use thereof
|
SG10201407453TA
(en)
|
2009-11-13 |
2014-12-30 |
Genosco |
Kinase inhibitors
|
EP2552214A4
(en)
*
|
2010-03-26 |
2013-10-16 |
Glaxo Group Ltd |
Pyrazolyl-pyrimidines as kinase inhibitors
|
EP2552211A4
(en)
*
|
2010-03-26 |
2013-10-23 |
Glaxo Group Ltd |
Indazolyl-pyrimidines as kinase inhibitors
|
EP3144298A1
(en)
|
2010-08-10 |
2017-03-22 |
Celgene Avilomics Research, Inc. |
Besylate salt of a btk inhibitor
|
UY33549A
(en)
*
|
2010-08-10 |
2012-01-31 |
Glaxo Group Ltd |
QUINOLIL AMINAS AS INHIBITING AGENTS OF KINASES
|
JP5956999B2
(en)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
Heteroaryl compounds and uses thereof
|
MX2013004894A
(en)
|
2010-11-01 |
2013-10-17 |
Celgene Avilomics Res Inc |
Heterocyclic compounds and uses thereof.
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
US8796255B2
(en)
|
2010-11-10 |
2014-08-05 |
Celgene Avilomics Research, Inc |
Mutant-selective EGFR inhibitors and uses thereof
|
PT2646448T
(en)
|
2010-11-29 |
2017-10-04 |
Osi Pharmaceuticals Llc |
Macrocyclic kinase inhibitors
|
WO2012083117A1
(en)
|
2010-12-16 |
2012-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
CA2829131C
(en)
|
2011-03-04 |
2018-11-20 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Amino-quinolines as kinase inhibitors
|
WO2012120044A1
(en)
*
|
2011-03-07 |
2012-09-13 |
Fondazione Telethon |
Tfeb variants and uses thereof
|
JP5999177B2
(en)
|
2011-05-04 |
2016-09-28 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Compound for inhibiting cell proliferation of EGFR-activated cancer
|
BR112014000115A2
(en)
|
2011-07-05 |
2016-10-04 |
Vertex Pharma |
processes and intermediates for the production of azaindoles, and their solid forms
|
EP2755939A4
(en)
|
2011-07-14 |
2015-04-15 |
Keith R Latham |
Halogenated phenols for diagnostics, antioxidant protection and drug delivery
|
HUE052198T2
(en)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology Inc |
Heterocyclic protein kinase inhibitors
|
UA118010C2
(en)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
INFLUENCES OF INFLUENZA VIRUS REPLICATION
|
TWI547494B
(en)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
Amino quinazolines as kinase inhibitors
|
EP2754659A4
(en)
*
|
2011-09-05 |
2015-08-26 |
Zhejiang Hisun Pharm Co Ltd |
4-substituted-(3-substituted-1h-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof
|
BR112014007310A2
(en)
*
|
2011-09-27 |
2017-04-04 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as mutant idh inhibitors
|
AR088570A1
(en)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE
|
KR101401664B1
(en)
*
|
2011-11-15 |
2014-06-11 |
중앙대학교 산학협력단 |
Novel pyrimidine-2,4-diamine derivatives for differentiation of neural stem cells and medical use thereof
|
UY34632A
(en)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
|
JP6317319B2
(en)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
Solid forms of epidermal growth factor receptor kinase inhibitors
|
MX356179B
(en)
|
2012-03-15 |
2018-05-17 |
Celgene Avilomics Res Inc |
Salts of an epidermal growth factor receptor kinase inhibitor.
|
JP6469567B2
(en)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Compound for inhibiting cell proliferation of EGFR-activated cancer
|
US9487504B2
(en)
|
2012-06-20 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Imidazolyl analogs as syk inhibitors
|
WO2013192125A1
(en)
*
|
2012-06-20 |
2013-12-27 |
Merck Sharp & Dohme Corp. |
Pyrazolyl derivatives as syk inhibitors
|
AR092529A1
(en)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
AMINOQUINAZOLINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOSITE FOR THE PREPARATION OF A MEDICINAL PRODUCT
|
AR092530A1
(en)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
EP2922847A1
(en)
|
2012-11-20 |
2015-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
WO2014081906A2
(en)
*
|
2012-11-21 |
2014-05-30 |
Ptc Therapeutics, Inc. |
Substituted reverse pyrimidine bmi-1 inhibitors
|
US9512136B2
(en)
*
|
2012-11-26 |
2016-12-06 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
EP2935226A4
(en)
|
2012-12-21 |
2016-11-02 |
Celgene Avilomics Res Inc |
Heteroaryl compounds and uses thereof
|
CN105188371A
(en)
|
2013-02-08 |
2015-12-23 |
西建阿维拉米斯研究公司 |
Erk inhibitors and uses thereof
|
KR20150118152A
(en)
|
2013-02-21 |
2015-10-21 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
Quinazolines as kinase inhibitors
|
EP2970240B1
(en)
|
2013-03-14 |
2018-01-10 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
BR112015022483A2
(en)
*
|
2013-03-14 |
2017-07-18 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as mutant idh inhibitors
|
KR102334260B1
(en)
*
|
2013-03-14 |
2021-12-02 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Jak2 and alk2 inhibitors and methods for their use
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
WO2014181813A1
(en)
*
|
2013-05-10 |
2014-11-13 |
武田薬品工業株式会社 |
Heterocyclic compound
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
EP3039015B1
(en)
|
2013-08-30 |
2019-10-30 |
PTC Therapeutics, Inc. |
Substituted pyrimidine bmi-1 inhibitors
|
JP6618901B2
(en)
|
2013-11-13 |
2019-12-11 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Methods for preparing inhibitors of influenza virus replication
|
PL3068776T3
(en)
|
2013-11-13 |
2019-10-31 |
Vertex Pharma |
Inhibitors of influenza viruses replication
|
US10584115B2
(en)
|
2013-11-21 |
2020-03-10 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine BMI-1 inhibitors
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
ES2741785T3
(en)
|
2014-08-13 |
2020-02-12 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
LT3604294T
(en)
*
|
2014-10-13 |
2021-07-26 |
Yuhan Corporation |
Compounds and compositions for modulating egfr mutant kinase activities
|
CN105085489B
(en)
*
|
2014-11-05 |
2019-03-01 |
益方生物科技(上海)有限公司 |
Pyrimidine or pyridine compounds and their, preparation method and medical usage
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
WO2016149756A1
(en)
*
|
2015-03-23 |
2016-09-29 |
The University Of Melbourne |
Treatment of respiratory diseases
|
EP3294717B1
(en)
|
2015-05-13 |
2020-07-29 |
Vertex Pharmaceuticals Inc. |
Methods of preparing inhibitors of influenza viruses replication
|
EP3294735B8
(en)
|
2015-05-13 |
2022-01-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
EP3323817B1
(en)
*
|
2015-07-16 |
2022-10-19 |
Chia Tai Tianqing Pharmaceutical Group Co.,Ltd |
Aniline pyrimidine derivatives and uses thereof
|
CN105061506B
(en)
*
|
2015-07-27 |
2017-08-29 |
苏州明锐医药科技有限公司 |
Antineoplastic AP26113 preparation method
|
LT3371171T
(en)
|
2015-11-02 |
2024-01-10 |
Blueprint Medicines Corporation |
Inhibitors of ret
|
CN106699810A
(en)
*
|
2015-11-17 |
2017-05-24 |
清华大学 |
Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity
|
KR20180098679A
(en)
|
2016-01-22 |
2018-09-04 |
잔센파마슈티카엔.브이. |
New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
|
HUE047684T2
(en)
|
2016-01-22 |
2020-05-28 |
Janssen Pharmaceutica Nv |
New substituted cyanoindoline derivatives as nik inhibitors
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
US10183928B2
(en)
|
2016-03-17 |
2019-01-22 |
Blueprint Medicines Corporation |
Inhibitors of RET
|
AU2017289317B2
(en)
|
2016-06-30 |
2021-04-01 |
Janssen Pharmaceutica Nv |
Cyanoindoline derivatives as NIK inhibitors
|
EP3478675B1
(en)
|
2016-06-30 |
2020-04-22 |
Janssen Pharmaceutica NV |
Heteroaromatic derivatives as nik inhibitors
|
WO2018017983A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to ret
|
US10035789B2
(en)
|
2016-07-27 |
2018-07-31 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
JP2020502116A
(en)
*
|
2016-12-19 |
2020-01-23 |
イソキュア バイオサイエンシーズ インク. |
Inhibition of mutant isocitrate dehydrogenase and compositions and methods thereof
|
KR20200139749A
(en)
|
2018-04-03 |
2020-12-14 |
블루프린트 메디신즈 코포레이션 |
RET inhibitors for use in treating cancer with RET alteration
|
BR112020020246A8
(en)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
AXL KINASE INHIBITORS AND THEIR USE
|
EP3773560A4
(en)
|
2018-04-13 |
2022-01-19 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
|
CN108864052A
(en)
*
|
2018-06-07 |
2018-11-23 |
福建医科大学 |
A kind of synthesis and application of the fluorescence probe for GC33-3-1 antibody with specific recognition
|
KR20210038906A
(en)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Methods of treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use therein
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
JP2022520361A
(en)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
Pharmaceuticals containing heterocyclic protein kinase inhibitors
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
PE20221010A1
(en)
|
2019-08-14 |
2022-06-15 |
Incyte Corp |
IMIDAZOLIL PYRIMIDINILAMINE COMPOUNDS AS CDK2 INHIBITORS
|
CN110746402B
(en)
*
|
2019-09-21 |
2021-01-15 |
温州医科大学 |
2-N-aryl-4-N-aryl-5-fluoropyrimidine compound and preparation method and application thereof
|
CN110669038B
(en)
*
|
2019-09-21 |
2020-10-30 |
温州医科大学 |
Pyrimidine FGFR4V550LInhibitor, preparation method and application thereof
|
JP2022551668A
(en)
|
2019-10-11 |
2022-12-12 |
インサイト・コーポレイション |
Bicyclic amines as CDK2 inhibitors
|